A simple treatment algorithm may help reduce treatment disparities for Hispanic and Black people with multiple sclerosis (MS), according to a preliminary study released today, March 3, 2025, that will ...
For years, researchers have been hopeful they could get under the hood of multiple sclerosis. The neurological condition shows up in over 2.5 million people around the world, but it doesn’t always ...
A novel program provided evidence that addressing long-known disparities in high-efficacy multiple sclerosis (MS) treatment for minority populations is a solvable problem. The program, presented by ...
Researchers have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel combined therapy. The results build on two harmonized Phase I clinical trials, focusing on ...
Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...
DelveInsight's“ Multiple Sclerosis Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Multiple Sclerosis pipeline landscape. It covers the ...
Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS). Kathy Zackowski, ...
Professional societies of neurologists, including most prominently the American Academy of Neurology (AAN) and the European Academy of Neurology (EAN) periodically release recommendations to guide ...
A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis (MS) in Finland between 2013 and 2022. According to the study published in ...
Pre-clinical studies using a small molecule drug have shown promise as a potential new treatment for multiple sclerosis (MS). CAMH-led pre-clinical studies using a small molecule drug have shown ...
As a medium, the Internet neither helps nor harms in multiple sclerosis care - what matters is how clinicians and patients engage in that medium, according to Paul Wicks, PhD, vice president of ...